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Abstract
During aging, intracranial volume remains unchanged and represents maximally attained brain
size, while various interacting biological phenomena lead to brain volume loss. Consequently,
intracranial volume and brain volume in late life reflect different genetic influences. Our genome-
wide association study in 8,175 community-dwelling elderly did not reveal any genome-wide
significant associations (p<5*10−8) for brain volume. In contrast, intracranial volume was
significantly associated with two loci: rs4273712 (p=3.4*10−11), a known height locus on
chromosome 6q22, and rs9915547, tagging the inversion on chromosome 17q21 (p=1.5*10−12).
We replicated the associations of these loci with intracranial volume in a separate sample of 1,752
older persons (p=1.1*10−3 for 6q22 and p=1.2*10−3 for 17q21). Furthermore, we also found
suggestive associations of the 17q21 locus with head circumference in 10,768 children (mean age
14.5 months). Our data identify two loci associated with head size, with the inversion on 17q21
also likely involved in attaining maximal brain size.
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Main text
During early development and maturation, brain growth is the major force for increasing
intracranial volume.1–2 This process, which begins in utero, continues throughout childhood
and ends in early adulthood resulting in an intracranial volume that remains essentially
unchanged throughout the remainder of life. During early life, intracranial volume is highly
associated with brain volume. However, unlike intracranial volume, brain volume starts to
decrease after early adulthood.3 The greatest loss occurs in advanced age and is associated
with disease states under polygenic and environmental influences, such as cerebrovascular
and neurodegenerative diseases that result in brain atrophy.3–4 As a consequence, the degree
of association between intracranial volume and brain volume declines with advancing age.
While intracranial volume and brain volume are both highly heritable,5–6 the genetic
influences on these measures may differ.
To assess the genetic influence on these two measures, we performed a genome-wide
association study on cross-sectional measures of intracranial volume and brain volume in the
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium.7
This consortium brings together six population-based cohort studies, of which five
participated in the current analysis:8–9 the Aging Gene-Environment Susceptibility-
Reykjavik Study (AGES-RS), the Atherosclerosis Risk in Communities (ARIC) Study, the
Austrian Stroke Prevention Study (ASPS), the Framingham Heart Study (FHS), and the
Rotterdam Study (RS). The current report includes 8,175 persons of European descent with
genome-wide genotype data and a quantitative measure of intracranial volume based on
magnetic resonance imaging (MRI). For brain volume, we further excluded persons
diagnosed with dementia or who had a cortical infarct on MRI. Moreover, brain volume was
expressed as a percentage of intracranial volume to exclude genetic influences on
intracranial volume. The ASPS only has data available regarding brain volume and not
intracranial volume, giving a total of 8,673 persons for the current GWAS on brain volume
(Table 1).
Data for replication are from a separate sample of 1,752 older subjects from AGES-RS, who
had undergone MRI, but not genome-wide genotyping. Additionally, we investigated
whether any of the significant loci associated with intracranial volume or brain volume were
also associated with head circumference in 10,768 children with an average age of 14.5
months from the EGG-consortium.10 Rather than a formal replication this analysis adds
veracity to the association of the discovered loci with human brain development. Finally,
since head size is a morphological phenotype related to adult height we verified whether any
significant loci for intracranial volume were already implicated for height in the GIANT-
consortium;11 we performed additional height-adjusted analyses for the SNPs achieving
genome-wide significance; and additionally we examined the association with intra-cranial
volume of all known loci for adult height.
Within CHARGE, after quality control each study imputed their genome-wide genotype
data to 2.2 million HapMap CEU SNPs using automated software. Subsequently, each study
ran genome-wide association tests for intracranial volume and brain volume using linear
regression. Each study used the same basic additive genetic model of dosages of the risk
allele with a 1 degree-of-freedom trend test, adjusting for age, sex, and familial relationships
(for FHS). From each study we examined quantile-quantile (Q-Q) plots for brain volume
and intracranial volume to ensure that the p-value distributions conformed to a null
distribution at all but the extreme tail (Supplementary Figure 1). Finally, results across
studies were meta-analyzed using inverse-variance weighting after performing genomic
control in each study. Examination of the Q-Q plots post meta-analysis showed an excess of
extreme p-values but no evidence of systematic inflation of the genomic control inflation
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factor (λ=1.04 for intracranial volume and 1.02 for brain volume; Supplementary Figure 2).
The genome-wide plots of p-values for the individual SNPs against their genomic position
are shown in Figures 1a and b. We did not observe any genome-wide significant association
for brain volume, although 46 SNPs reached p<10−5 (Supplementary Table 1).
For intracranial volume, 720 SNPs located in two loci surpassed our preset threshold of
genome-wide significance (p<5*10−8). An additional 200 SNPs showed associations with
p<10−5 (Supplementary Table 2).
The most significant association with intracranial volume was identified for rs9915547 on
chromosome 17. The minor allele of this SNP (MAF=0.22) was significantly associated
with smaller intracranial volume (p=1.5*10−12). This SNP belongs to an almost 1Mb large
cluster of SNPs in very strong LD with each other located in a region that has previously
been identified as the chromosome 17q21 inversion (Figure 2a). The chromosome 17q21
inversion consists of two haplotypes (H1 and H2) with the minor allele of rs9915547
tagging the H2 haplotype. Adjusting for height did not change this result
(padjusted for height=1.8*10−12).
The second genome-wide significant association was found for rs4273712 on chromosome
6q22, with RSPO3 and C6Orf173 being the closest genes (Figure 2b). The minor allele of
this SNP (MAF=0.27) was associated with a larger intracranial volume (p=3.4*10−11). This
locus has previously been associated with adult height.11 Interestingly, copy number
variations (CNV) have been reported at this locus, the closest of which are at position
127124970-127135701 and 127136191-127141042.
Both rs9915547 (p=0.23) and rs4273712 (p=0.67) were not associated with brain volume in
our data.
We sought to replicate the genome-wide significant associations in a sample of 1752 older
persons from AGES-RS, who were not included in the discovery sample. We genotyped
rs4273712 and rs9303525 (pdiscovery=1.6*10−12), which tags the inversion in perfect LD
with rs9915547, and replicated their association with intracranial volume: P=1.1*10−3 for
rs4273712 and 1.2*10−3 for rs9303525); the meta-meta-analysis of the replication sample
with the discovery samples yielded p-values of 1.8*10−13 for rs4273712 and 7.6*10−15 for
rs9303525 (Table 2).
Finally, given the hypothesis that intracranial volume is reflective of the maximum brain
size during life, we reasoned that these loci may play a role in brain growth. Therefore, we
investigated associations of these loci with head circumference in 10,768 children from the
EGG-consortium,10 where head circumference is much more likely to be a direct marker for
brain growth.1 We found that rs9915547 was significantly associated with head
circumference (p=5.3*10−3). In this birth cohort, the most significant SNP located within the
17q21 inversion was rs11655470 with p=1.4*10−6, though this SNP does not accurately tag
the inversion itself (r2 with the inversion is 0.22 according to HapMap CEU).10 Indeed,
within CHARGE rs11655470 was only weakly associated with intracranial volume at
p=0.04. To investigate whether these signals were independent, we performed conditional
analyses for rs9915547 and rs11655470 and found p=6.3*10−15 and p=0.38, respectively.
The attenuation for rs11655470 suggests that the association is primarily driven by
rs9915547, which tags the inversion.
No association was found for rs4273712 with head circumference in the EGG-consortium
(p=0.16). Because rs4273712 is located in a known height locus, we also looked up the
association with intracranial volume of all 180 known loci for adult height.11 These results
are presented in Supplementary Table 3. Apart from the 6q22 locus only rs1351394 on
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chromosome 12 was nominally significantly associated with intracranial volume
(p=4.7*10−6; threshold for Bonferroni-adjusted significance 0.05/180=2.8*10−4).
Interestingly, another SNP at this locus (rs1042725) was genome-wide significantly
associated with head circumference in the EGG-consortium (p=2.8*10−10).10 The r2
between these rs1042725 and rs1351394 is 0.91 based on CEU HapMap2.
Several genes are located in the 17q21 inversion, which is tagged by two haplotypes (H1
and H2). The two haplotypes show different expression patterns of these genes, some of
which have been implicated in neuro-degenerative disorders in late life, particularly among
individuals with the H1 haplotype.12 This region includes MAPT which encodes the tau
protein, a major hallmark of various dementias, including Alzheimer’s disease and fronto-
temporal dementia.12–14 Mutations in MAPT have been consistently associated with fronto-
temporal dementia, progressive supra-nuclear palsy and Parkinson’s disease.15 This region
also includes GRN which encodes progranulin, mutations in which can also cause fronto-
temporal degeneration.16–17 Additional genes in the 17q21 inversion region include
corticotrophin releasing hormone receptor 1 (CRHR1), a gene that has been associated with
early brain development and may mediate response to environmental stress;18 and saitohin
(STH) which has been associated with an increased risk of late-onset Alzheimer’s disease
and with progressive supranuclear palsy.14–15 In addition, smaller intracranial volume has
been consistently associated with an increased risk for late-life dementia19 suggesting that at
least some of the findings related to intracranial volume and dementia risk may reflect the
impact of this inversion on early development. Finally, several microdeletions within the
inversion have been shown to cause microencephaly and various childhood mental
retardation syndromes.20–21
The population genetics and the evolutionary history of this inversion are the object of
ongoing research with some studies suggesting that this inversion is about 3 million years
old and almost exclusively present in the Caucasian population,22 although more recent
work suggests contests this notion.23 Moreover, findings that the H2 haplotype is
undergoing positive selection in some Caucasians populations,22 have also recently been
contested with the alternative explanation that the higher H2 frequency is a founder effect.23
The influence of the inversion on brain development as shown in our study might be
hypothesized as one mechanism to explain the putative positive selection. However, this is
less likely since the H2 haplotype is associated with a smaller intracranial volume, whereas
intracranial volume has increased throughout evolution of the primates to homo sapiens.24
Still, our finding provides further insights into the role of the 17q21 inversion in human
biology. More research is needed to determine its exact role.
Thus far, in order to explain our findings regarding 17q21 we have focused primarily on
neurological mechanisms, assuming that brain growth drives intracranial volume. An
alternative explanation is that variations in bone growth determine both intracranial volume
and thus maximum brain volume. However, given that this inversion does not seem to
influence height11 and that height is particularly influenced by bone growth, this alternative
explanation appears unlikely.
Two loci implicated in height were also associated with intracranial volume. This suggests
potential overlap in the function for the chromosomes 6 and 12 loci and brain development.
Rs4273712 on chromosome 6 is close to the gene RSPO3 encoding a protein of the
thrombospondin type 1 repeat supergene family, which appear to play a role in the
development of the nervous system.25 Another potentially interesting gene in this region is
RNF146, which lies further downstream from RSPO3 and has shown to be upregulated in
brains of Alzheimer’s disease patients.26 We also note that reported CNVs could explain the
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association pattern seen at chr6q22, with the region showing high linkage disequilibrium
(LD) without any SNP in clear LD with rs4273712.
The chromosome 12 locus tags a gene which encodes a protein belonging to the non-histone
chromosomal high mobility group (HMG) protein family. This gene has been implicated in
height, adipogenesis and mesenchymal differentiation. Though this locus did not reach
genome-wide significance with intracranial volume, it was associated at genome-wide
significance with head circumference in children.10 This further demonstrates overlap in
genetic variants that influence head size in childhood, maximum head size in adulthood, and
possibly brain growth.
In conclusion, this genome-wide association study identified the chromosome 17 inversion
as strongly associated with intracranial volume. We further found that this inversion may
play a role in early life brain growth. A second genome-wide significant association was
found for rs4273712 on chromosome 6 near RSPO3 and RNF146, both potentially
interesting genes in neuronal development and degeneration.
Online Methods
Participating Cohorts
Analyses were performed among participants of studies in the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) consortium.7 Details on the 6 participating
discovery samples, the replication and extension samples can be found in the Supplementary
Note. Each study has an Institutional Review Board that approved the consent procedures,
examination components, data security processes, genotyping protocols and current study
design. All participants gave written informed consent for study participation and for use of
DNA for genetic research.
Measurement of intracranial volume and brain volume on magnetic resonance imaging
Each study performed brain magnetic resonance imaging (MRI) on scanners ranging from
0.5 to1.5 T in field strength. Each study used its own custom-made or freely downloadable
fully automatic or semi-quantitative MRI post-processing software to measure intra-cranial
volume and brain volume. Brain volume was expressed as percentage of intracranial volume
in order to correct for individual head-size differences in all studies. Due to the software
used, the Austrian Stroke Prevention Study only had measurements available for brain
volume. All software have been extensively validated against manual tracings, the gold
standard for automated MRI post-processing algorithms. We note that any remaining
heterogeneity across studies due the differences in post-processing algorithms would lead to
lower power; this in turn could lead to false-negatives, but would not invalidate the
associations that were found.
Specific details for each study’s MRI protocol are provided in the Supplementary Note. The
correlation between intracranial volume (in milliliters) and brain volume (in milliliters) was
0.83 for AGES, 0.88 for ARIC, 0.89 for FHS, 0.91 for RS I, 0.92 for RS II, 0.95 for RS III.
In contrast when using brain volume expressed as percentage of intracranial volume, as was
done in our GWAS, the correlations strongly attenuated and became −0.35 for AGES, −0.29
for ARIC, −0.01 for FHS, 0.04 for RS I, −0.19 for RS II, and −0.17 for RS III.
Genotyping, quality controls, and imputation
The consortium was formed after the individual studies had finalized their GWAS platforms,
and the 6 studies included used different platforms: the Illumina Human 370-Duo
BeadChip® for AGES-Reykjavik Study; the Affymetrix GeneChip SNP Array 6.0® for
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ARIC; the Illumina Human610-Quad BeadChip® for ASPS; the Affymetrix GeneChip
Human Mapping 500K Array Set® and 50K Human Gene Focused Panel® for FHS; and the
Illumina HumanHap550 Duo BeadChip® for the Rotterdam Study.
As detailed previously,8–9 participant-specific quality controls included filters for call rate,
heterozygosity, and number of Mendelian errors per individual. SNP-specific quality
controls included filters for call rate, minor allele frequency, Hardy-Weinberg equilibrium,
and differential missingness by outcome or genotype (mishap test in PLINK, http://
pngu.mgh.harvard.edu/purcell/plink/).
The set of genotyped input SNPs used for imputation in each study was selected based on
their highest quality GWA data. We used a call rate >95% in ARIC, >97% in FHS, and
>98% in AGES-Reykjavik, ASPS, and Rotterdam; a minor allele frequency >0.01 in each
study; a Hardy-Weinberg p>1x10−6 in AGES-Reykjavik, ARIC, ASPS, FHS, and
Rotterdam; and a test of differential missingness by the “mishap” test in PLINK p>1x10−9 in
each study. We used the Markov Chain Haplotyping (MaCH) package (http://
www.sph.umich.edu/csg/abecasis/MACH, version 1.0.15 or 1.0.16 software) for AGES-
Reykjavik, ARIC, ASPS, FHS and Rotterdam imputed to plus strand of NCBI build 36,
HapMap release #22. Imputation of genotypes provides a dosage value for every SNP
between 0 and 2 indicating the expected value of a SNP being homozygous for the reference
allele. For each imputed SNP an assessment of the informativeness of the imputation was
estimated (as the ratio of the empirically observed dosage variance to the expected binomial
dosage variance, O/E ratio).
For the primary meta-analysis using inverse-variance weighting less weight is given to
imputed SNPs with low O/E ratio resulting in higher variance of the estimate.
Studies were screened for latent population substructure,8–9 including cryptic relatedness,
using suitable programs: EIGENSTRAT in ARIC, FHS and AGES-Reykjavik, and IBD
matrix in ASPS and Rotterdam. When appropriate, components related to ICV or brain
volume were included as covariates in the linear regression.
We studied the quantile-quantile (QQ) plots to ensure that the p-value distributions in each
of the cohorts conformed to a null distribution at all but the extreme tail.
We also calculated the genomic inflation factor lambda, which measures over-dispersion of
test-statistics from association tests indicating population stratification and can be used to
apply genomic control.
Analysis within studies
Each study ran a 1-degree of freedom additive association models of the GWAS with
intracranial volume and brain volume. Alleles were used as dosages of 0, 1, or 2 copies of
the risk allele. Intracranial volume was expressed in milliliters, whereas brain volume was
expressed as percentage of intracranial volume to correct for individual head size
differences. We note that the SIENAX software used in ASPS only provides this estimate of
atrophy and no absolute volumes in milliliters. All models were adjusted for age and sex and
– in the Framingham Heart Study – for familial relationships. In secondary analyses, we
additionally adjusted for height.
Discovery meta-analysis
After quality control and filtering within each study, AGES-Reykjavik had either genotyped
or imputed data for 2,408,992 SNPs, ARIC for 2,298,221 SNPS, ASPS for 2,317,924 SNPs,
FHS for 2,543,888 SNPs, the Rotterdam study I for 2,543,888 SNPs, the Rotterdam study II
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for 2,543,888 SNPs, and the Rotterdam study III for 2,543,888 SNPs. We restricted the
present meta-analysis to the 2,229,753 autosomal SNPs common to all studies. For our
discovery meta-analysis we used the technique of inverse-variance weighting assuming
fixed-effects, after applying genomic control within each individual study. Beta estimates
were weighted by their inverse variance and a combined estimate was obtained by summing
the weighted betas and dividing by the summed weights. Hence results for SNPs imputed
with low certainty were down-weighted because the low reliability-of-imputation ensures a
large variance. In contrast, studies with large sample sizes and with directly genotyped or
well-imputed SNPs had a greater effect on the meta-analyses p-value because of small
variances. We undertook the meta-analysis at Rotterdam using the R-package MetABEL.
We estimated the genomic inflation factor lambda after meta-analysis. The estimate of
lambda was 1.039 for ICV and 1.019 for brain volume indicating no significant inflation of
p-values. We also examined Q-Q plots of the results from the meta-analysis: for intracranial
volume, the original QQ-plot was driven for a large part by the chromosome 17 inversion
and the numerous SNPs in close LD in that region. Therefore, we recalculated the QQ-plot
after excluding the chromosome 17 inversion.
Replication analysis and extension analysis
The replication sample consisted of a random subset of 1607 white participants from the
AGES-Reykjavik study, who had not undergone genome-wide genotyping at the time of the
study, but had MRI scans with measurement of intracranial volume available. Methods for
measurements of intracranial volume were the same as for the rest of the AGES-Reykjavik
study. Using TaqMan assays we genotyped rs4273712 and rs9303535 (pdiscovery=1.6*10−12)
which tags the chromosome 17 inversion in perfect linkage disequilibrium with rs9915547
(r2=1 and D’=1 between these two SNPs). We ran 1-degree of freedom additive association
relating these SNPs to intracranial volume Thresholds for statistical significance were set at
p<0.025 (Bonferoni correction for two SNPs). Subsequently, results from the replication
sample were meta-analyzed with the discovery sample using fixed-effect inverse variance
meta-analysis.
For extension of our samples we examined genome-wide significant loci from the discovery
analysis in an existing meta-analysis on head circumference during infancy in 10,768
children (mean age 14.5 months).10 Here too, thresholds for statistical significance were set
at p<0.025. Head circumference was measured manually.
Association of reported height loci with intracranial volume
Because head size is a morphological phenotype related to adult height, we also examined
all loci that were recently reported to be associated with adult height for their association
with intracranial volume.11 A total of 180 SNPs were tested, resulting in a Bonferoni-
corrected p-value of 0.05/180=2.8*10−4 as threshold for significance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Ed. Summary: M. Arfan Ikram and colleagues report a genome-wide association study for
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Figure 1.
a and b. Genome-wide signal intensity (Manhattan) plots showing the individual p-values
(based on the fixed-effects meta-analysis) against their genomic position for brain volume
(a) and intracranial volume (b). Within each chromosome, shown on the x-axis, the results
are plotted left to right from the p-terminal end. The horizontal lines indicate thresholds for
p=10−4, p=10−5, and p=5*10−8 (genome-wide significant).
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Figure 2. a and b. Regional plots for the genome-wide significant associations with intracranial
volume
All SNPs (circles) are plotted with their meta-analysis p-values against their genomic
position. Circles are color-coded according to their linkage disequilibrium with the top SNP
(purple rectangle) as follows: r2<0.2 darkblue; 0.2<r2<0.4 lightblue; 0.4<r2<0.6 green;
0.6<r2<0.8 orange; 0.8<r2 red. The blue line at the bottom of the graph represents the
estimated recombination rates. Gene annotations are shown as the black arrows.
We note that several copy number variations have been reported at chr6q22, the closest of
which are downstream of rs4273712 at position 127124970-127135701 and
127136191-127141042.
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